Galera Therapeutics, Inc. (GRTX)
GRTX Stock Price Chart
Explore Galera Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GRTX price movements and trends.
GRTX Company Profile
Discover essential business fundamentals and corporate details for Galera Therapeutics, Inc. (GRTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Nov 2019
Employees
3.00
Website
https://www.galeratx.comCEO
J. Mel Sorensen
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
GRTX Financial Timeline
Browse a chronological timeline of Galera Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Dec 2025
Earnings released on 13 Aug 2025
EPS came in at -$0.01 .
Earnings released on 15 May 2025
EPS came in at -$0.01 .
Earnings released on 31 Mar 2025
EPS came in at -$0.08 surpassing the estimated -$0.30 by +73.33%.
Earnings released on 13 Dec 2024
EPS came in at -$0.06 surpassing the estimated -$0.29 by +79.31%.
Earnings released on 14 Aug 2024
EPS came in at -$0.07 falling short of the estimated $0.83 by -108.46%.
Earnings released on 13 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.29 by +72.83%.
Earnings released on 28 Mar 2024
EPS came in at -$0.10 surpassing the estimated -$0.29 by +64.95%, while revenue for the quarter reached $88.00K .
Earnings released on 14 Nov 2023
EPS came in at -$0.33 surpassing the estimated -$0.44 by +25.00%.
Earnings released on 14 Aug 2023
EPS came in at -$0.48 falling short of the estimated -$0.43 by -11.63%.
Earnings released on 11 May 2023
EPS came in at -$0.50 falling short of the estimated -$0.36 by -38.89%.
Earnings released on 8 Mar 2023
EPS came in at -$0.58 falling short of the estimated -$0.50 by -16.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.60 falling short of the estimated -$0.48 by -25.00%.
Earnings released on 9 Aug 2022
EPS came in at -$0.54 falling short of the estimated -$0.47 by -14.89%.
Earnings released on 16 May 2022
EPS came in at -$0.58 falling short of the estimated -$0.53 by -9.43%.
Earnings released on 10 Mar 2022
EPS came in at -$0.64 surpassing the estimated -$0.75 by +14.67%.
Earnings released on 10 Nov 2021
EPS came in at -$0.86 falling short of the estimated -$0.65 by -32.31%.
Earnings released on 10 Aug 2021
EPS came in at -$0.88 falling short of the estimated -$0.79 by -11.39%.
Earnings released on 11 May 2021
EPS came in at -$0.75 surpassing the estimated -$0.82 by +8.54%.
Earnings released on 11 Mar 2021
EPS came in at -$0.80 falling short of the estimated -$0.66 by -21.21%.
Earnings released on 10 Nov 2020
EPS came in at -$0.69 surpassing the estimated -$0.77 by +10.39%.
GRTX Stock Performance
Access detailed GRTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.